

North Central Cancer Treatment Group

N057K: Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ)
Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

Revised Status Change Notice – January 24, 2012

NOTICE OF STATUS CHANGE

This study is reopened to patient accrual **at Mayo Clinic Rochester only** effective January 24, 2012 due to the resumption of the delivery of Afinitor[®] (everolimus; RAD001) investigational drug re-supply from the sponsor Novartis.

Please retain this notice with the protocol.